PARAMUS, N.J., Oct. 4, 2012 /PRNewswire/ -- PROTEONOMIX,
INC. (OTCBB: PROT), a biotechnology company focused on developing
therapeutics based upon the use of human cells and their
derivatives, announced today that the Company's clinical trial of
UMK-121 has received IRB (Institutional Review Board) approval and
is now ready for the recruitment of patients.
We thank the University of Medicine &
Dentistry of New Jersey for providing the IRB and their
invaluable contribution to this study of the UMK-121 drug therapy
on patients with End Stage Liver Disease.
To better understand what a clinical trial is please visit the
following links: Overview; Rising Cost of Clinical Trial;
Additional information on Clinical Trials .
As previously announced, the Company entered into an Agreement
to conduct the clinical trial with the UMDNJ. That Agreement
required the Company to pay expenses associated with the clinical
study which the Company has done to date.
Michael Cohen, President of the
Company, stated: "The financing that was required to complete the
Company's obligation with respect to the Trial was provided by the
private placement of our Series E Preferred Stock on Friday, March 9, 2012. We previously
announced that we have engaged the University to conduct the trial
and thanked the University for their assistance with the
finalization of the agreement to conduct a clinical trial of
UMK-121. The Company has previously described the terms of the
agreement to license and develop and the patent application of the
UMK-121 technology. The Company will work together with
the University and the principal investigators to initiate the
clinical study. The approval of the IRB was required before the
study could go forward. The investigators can now accept
patients into the study."
About the University of Medicine and
Dentistry of New Jersey
The University of Medicine and Dentistry of
New Jersey (UMDNJ) is New
Jersey's only health sciences university with more than
6,000 students on five campuses attending three medical schools,
the State's only dental school, a graduate school of biomedical
sciences, a school of health related professions, a school of
nursing and New Jersey's only
school of public health. UMDNJ operates University Hospital, a
Level I Trauma Center in Newark,
and University Behavioral HealthCare, which provides a continuum of
healthcare services with multiple locations throughout the
State.
About Proteonomix, Inc.
Proteonomix is a biotechnology company focused on developing
therapeutics based upon the use of human cells and their
derivatives. The Proteonomix family of companies includes
Proteoderm, StromaCel, PRTMI and THOR Biopharma. Proteoderm is a
wholly owned subsidiary that has developed an anti-aging line of
skin care products. StromaCel develops therapeutic modalities for
the treatment of cardiovascular disease and for treatment of
patients who have suffered post-myocardial infarction. Proteonomix
Regenerative Translational Medicine Institute, Inc. (PRTMI) intends
to focus on the translation of promising research in stem cell
biology and cellular therapy to clinical applications of
regenerative medicine. Additional information is available at
www.proteonomix.com and www.proteoderm.com.
Forward-looking statements:
Certain statements contained herein are "forward-looking
statements" (as defined in the Private Securities Litigation Reform
Act of 1995). Proteonomix, Inc. cautions that statements made in
this press release constitute forward-looking statements and makes
no guarantee of future performance. Actual results or developments
may differ materially from projections. Forward-looking statements
are based on estimates and opinions of management at the time
statements are made.
SOURCE Proteonomix, Inc.